217 related articles for article (PubMed ID: 28041631)
1. Targeting fibroblast growth factor pathways in endometrial cancer.
Winterhoff B; Konecny GE
Curr Probl Cancer; 2017; 41(1):37-47. PubMed ID: 28041631
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibition of fibroblast growth factor receptors in cancer.
Liang G; Chen G; Wei X; Zhao Y; Li X
Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
[TBL] [Abstract][Full Text] [Related]
3. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
4. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
5. Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway.
Lee PS; Secord AA
Cancer Treat Rev; 2014 May; 40(4):507-12. PubMed ID: 24332498
[TBL] [Abstract][Full Text] [Related]
6. [FGF/FGFR blockade: New insights in endometrial cancer].
Flippot R; Vignot S
Bull Cancer; 2015 Dec; 102(12):964-5. PubMed ID: 26617116
[No Abstract] [Full Text] [Related]
7. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
Dianat-Moghadam H; Teimoori-Toolabi L
Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
Salgia R
Cancer Med; 2014 Jun; 3(3):681-92. PubMed ID: 24711160
[TBL] [Abstract][Full Text] [Related]
9. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.
Mori M; Mori T; Yamamoto A; Takagi S; Ueda M
Hum Cell; 2019 Jul; 32(3):367-378. PubMed ID: 30963412
[TBL] [Abstract][Full Text] [Related]
10. Targeting FGFR Signaling in Cancer.
Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
[TBL] [Abstract][Full Text] [Related]
11. Advances and challenges in targeting FGFR signalling in cancer.
Babina IS; Turner NC
Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
13. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
[TBL] [Abstract][Full Text] [Related]
14. Recent developments and advances of FGFR as a potential target in cancer.
Xue WJ; Li MT; Chen L; Sun LP; Li YY
Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
[TBL] [Abstract][Full Text] [Related]
15. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
17. Endometrial Carcinoma: Specific Targeted Pathways.
Eritja N; Yeramian A; Chen BJ; Llobet-Navas D; Ortega E; Colas E; Abal M; Dolcet X; Reventos J; Matias-Guiu X
Adv Exp Med Biol; 2017; 943():149-207. PubMed ID: 27910068
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
20. Targeting the fibroblast growth factor receptor family in cancer.
Hallinan N; Finn S; Cuffe S; Rafee S; O'Byrne K; Gately K
Cancer Treat Rev; 2016 May; 46():51-62. PubMed ID: 27109926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
